U.S. Specialty Injectable Generics Market

The U.S. specialty injectable generic market size was USD 18.52 Billion in 2022 and is likely to reach USD 64.64 Billion by 2031, expanding at a CAGR of 14.9% during 2023–2031 attributed to the increase in the number of infectious diseases and chronic diseases such as hepatitis C, cancer, multiple sclerosis, and others. The expiration of branded drugs in the coming years is anticipated to act favorable conditions for the injectable market growth.

Injectable drugs involves the administration of drugs using a needle as a medium with the help of a syringe to a patient’s body. Injectable drugs are given and are preferred to use as drugs are directly introduced into the bloodstream that perform action immediately and effectively as compared to oral medications. Not only the U.S has well-developed healthcare facilities but also has favorable government rules and legislations for healthcare that help the patients to have easy access for injectable treatments. Due the increase in availability of generics in the market, the spending on specialty medications has also increased.

Get Free Sample Report

In order to prevent further spread of COVID-19, several pharmaceutical firms are collaborating with other companies to develop a vaccine and get approval of their drugs. These vaccines are more likely to be in the injectable form which is anticipated to fuel the growth of the market. For example, United States Health Department's Biomedical Advanced Research and Development Authority (BARDA) funded more than USD 1 billion in May 2020 for the development, production, and delivery of the COVID-19 vaccine by AstraZeneca that was collaborating with the Oxford University.

US Specialty Injectable Generics Market Trends, Drivers, Restraints, and Opportunities

• Increase in the demand for advanced therapies for the treatment of chronic diseases and rapid development of new products are some of the major driving factors of the market.

• Merging and collaborations done by major drug manufacturers with generic drug manufacturers is anticipated to boost the growth of the market.

• Rise in investment amount for research and development of developing anti-chronic drugs is another key driving factor of the market.

• Rise in prevalence of other conditions such as osteoporosis, rheumatoid, and infectious disease is another key factor helping in the growth of the market.

• Ordering & storing of injectable drugs are highly expensive is a major restraining factor that can hamper the growth of the market.

Scope of US Specialty Injectable Generics Market Report

The report on the U.S. specialty injectable generic market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

US Specialty Injectable Generics Market Segment Insights

Oncology segment is anticipated to dominate the market

On the basis of therapeutic uses, the U.S. specialty injectable generic market is segmented into cardio vascular, oncology, infectious diseases, central nervous system (CNS), autoimmune disorders, and others. The oncology segment held a major share of the market in 2019 and is anticipated to dominate the market in the coming years. The segment growth is attributed to an increase in the incidence of various types of cancer such as leukemia, melanoma, breast, prostate, colon, and lung cancer. An increase in demand for advanced technologies and new products launch for oncology are also expected to boost the segment growth. For example, the generic version of Clolar (clofarabine injection) was approved in May 2017 by the US Food and Drugs Administration, which was designed for the treatment of acute lymphoblastic leukemia.

Meanwhile, the CNS segment is anticipated to grow at a considerable growth rate during the targeted years attributed to the availability of substitutes for the treatment of neurological disorders at low cost. For example, InnoPharma, Inc. was acquired by Pfizer in 2014 for the development of injectable generics for the treatment of the CNS and cancer. Currently, only a few specialty injectable generics are available for the treatment of the CNS disorders.

However, the cardio vascular segment is expected to expand at a moderate growth rate in the near future attributed to the broad gap present between the demand and supply chain of specialty injectable generic for the treatment of cardio vascular diseases. As per the reports by the Centers for Disease Control and Prevention (CDC), the disease is responsible for nearly 310,000 deaths in the U.S every year. New opportunities have been created for the generics of cardio vascular diseases as strict restrictions and guidelines have been imposed on the initial prescriptions of cardio vascular diseases.

Get Free Sample Report

Segments

The U.S. disease specialty injectable generic market has been segmented on the basis of

Therapeutic Uses

• Cardio Vascular
• Oncology
• Infectious Diseases
• CNS
• Autoimmune Disorders
• Others

Country

• The US

Key Players

• Fresenius SE & Co. KGaA
• Pfizer Inc.
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.

Competitive Landscape

Key players competing in the U.S. specialty injectable generic market are Fresenius SE & Co. KGaA; Pfizer Inc.; Mylan N.V.; Hikma Pharmaceuticals PLC; and Teva Pharmaceutical Industries Ltd. Some of these players have adopted business strategies such as launching new products, introducing new technology, merger, partnership, and production capacity expansion to increase their market position and expand their consumer base globally.

For example, Hospira was acquired by Pfizer in September 2015 in order to expand the product portfolio of injectable generics. Another example is that the U.S. generic injectables business of Bedford Laboratories acquired Hikma Pharmaceuticals in May 2014 in order to strengthen the research & development and grow its product pipeline. Meanwhile, small to mid-sized companies are also constantly looking for some strategies such as collaboration to successfully commercialize their products.